Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s562002 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Qiao Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Everolimus, Nanoparticles, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Qiao Zeng, Wenying Yu, Qiao Wang
Zitieren
APA
Zeng, Q., Chen, J., Zhang, H., Yu, W., Xu, H., Wang, Q., & Tang, Z. (2025). Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s562002
Vancouver
Zeng Q, Chen J, Zhang H, Yu W, Xu H, Wang Q, et al. Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s562002
BibTeX
@article{Zeng2025,
author = {Zeng, Qiao and Chen, Jie and Zhang, Han and Yu, Wenying and Xu, Haonan and Wang, Qiao and Tang, Zhan},
title = {Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s562002}
}
EUVIMED